PPC
MCID: PRM126
MIFTS: 60

Primary Peritoneal Carcinoma (PPC) malady

Cancer diseases, Rare diseases categories
Download this MalaCard

Summaries for Primary Peritoneal Carcinoma

About this section


Fully expand this MalaCard
Wikipedia:65 Primary peritoneal cancer or carcinoma is also known as: serous surface papillary carcinoma, primary... more...

MalaCards based summary: Primary Peritoneal Carcinoma, also known as primary peritoneal serous carcinoma, is related to peritoneal carcinoma and papillary carcinoma, and has symptoms including anomalies of the abdominal wall, nausea/vomiting/regurgitation/merycism/hyperemesis and acute abdominal pain/colic. An important gene associated with Primary Peritoneal Carcinoma is BRCA1 (breast cancer 1, early onset), and among its related pathways are Homologous Recombination Repair and DNA Damage Induced 14-3-3Sigma Signaling. The compounds topotecan and vinorelbine have been mentioned in the context of this disorder. Affiliated tissues include ovary, brain and eye, and related mouse phenotypes are liver/biliary system and renal/urinary system.

Aliases & Classifications for Primary Peritoneal Carcinoma

About this section
Sources:
48Orphanet, 62UMLS, 26ICD10 via Orphanet
See all sources

Primary Peritoneal Carcinoma, Aliases & Descriptions:

Name: Primary Peritoneal Carcinoma 48 62
Primary Peritoneal Serous Carcinoma 48 62
Serous Surface Papillary Carcinoma 48 62
 
Ppc 48 62
Extra-Ovarian Primary Peritoneal Carcinoma 48
Eoppc 48


Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Cancer diseases, Rare diseases
Orphanet: 48 
Rare tumors


Characteristics (Orphanet epidemiological data):

48
primary peritoneal serous carcinoma:
Age of onset: Adulthood; Age of death: Normal


External Ids:

ICD10 via Orphanet26 C48.2

Related Diseases for Primary Peritoneal Carcinoma

About this section

Diseases in the Primary Peritoneal Carcinoma family:

Peritoneal Benign Neoplasm Peritoneal Carcinoma

Diseases related to Primary Peritoneal Carcinoma via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 131)
idRelated DiseaseScoreTop Affiliating Genes
1peritoneal carcinoma32.3BRCA1, BRCA2
2papillary carcinoma30.9BRCA2, PGR, MUC16, RET, ERBB2
3tuberculosis30.5IL10, IFNG, CXCL10
4endometriosis30.3PGR, MUC16, IL8
5ovarian cancer29.7TP53, BRCA2, BRCA1, PGR, MUC16, ERBB2
6adenocarcinoma29.1TP53, BRCA2, BRCA1, PGR, MUC16, CXCL10
7peritonitis11.1
8struma ovarii10.5MUC16
9adenofibroma10.5MUC16
10breast-ovarian cancer, familial, 110.5BRCA2
11ovarian serous cystadenocarcinoma10.5MUC16
12pleurisy10.5MUC16
13cystadenoma10.5BRCA1
14papillary serous adenocarcinoma10.5
15ovary papillary carcinoma10.5
16uterine fibroid10.5PGR
17cystadenocarcinoma10.5CEACAM5, MUC16
18papillary adenocarcinoma10.4MUC16, CEACAM5
19brca1 and brca2 hereditary breast and ovarian cancer10.4BRCA2, BRCA1
20endodermal sinus tumor10.4MUC16, CEACAM5
21fallopian tube cancer10.4BRCA2, BRCA1
22breast cancer10.4BRCA2, BRCA1
23neuroblastoma10.4TP53
24ovarian cystadenoma10.4BRCA1, MUC16
25lynch syndrome10.4BRCA2, BRCA1
26paracoccidioidomycosis10.4CXCL10, IL10
27meningitis10.3IL8, CXCL10
28dysgerminoma10.3BRCA1, BRCA2
29sex cord-gonadal stromal tumor10.3CEACAM5, PGR
30autosomal dominant disease10.3BRCA1, RET
31viral meningitis10.3CXCL10, IL8
32mammary paget's disease10.3PGR, ERBB2
33bronchiolitis obliterans10.3CXCL10, IL8
34li-fraumeni syndrome10.3PGR, ERBB2
35cervical adenocarcinoma10.3PGR, MUC16, CEACAM5
36hepatitis10.3
37in situ carcinoma10.3
38syphilis10.3
39tertiary syphilis10.3
40folliculitis10.3EGFR
41familial colorectal cancer10.3BRCA2, BRCA1, RET
42cowden disease10.3RET, BRCA1, BRCA2
43bilateral breast cancer10.3BRCA2, BRCA1, PGR
44gynecomastia10.2PGR, BRCA1, BRCA2
45gallbladder cancer10.2TP53, CEACAM5
46alcoholic hepatitis10.2IL10, IL8
47giant cell glioblastoma10.2EGFR
48tubular adenocarcinoma10.2ERBB2, CEACAM5, PGR
49gastric adenocarcinoma10.2MUC16, CEACAM5, ERBB2
50malignant pleural mesothelioma10.2MUC16, CEACAM5

Graphical network of the top 20 diseases related to Primary Peritoneal Carcinoma:



Diseases related to primary peritoneal carcinoma

Symptoms for Primary Peritoneal Carcinoma

About this section


Symptoms:

48 (show all 9)
  • anomalies of the abdominal wall
  • nausea/vomiting/regurgitation/merycism/hyperemesis
  • acute abdominal pain/colic
  • constipation
  • peritoneal diseases
  • neoplasms/tumors
  • ovary/fallopian tube neoplasm/tumor/carcinoma/cancer (excl. teratoma/germinoma)
  • weight loss/loss of appetite/break in weight curve/general health alteration
  • early death/lethality

HPO human phenotypes related to Primary Peritoneal Carcinoma:

(show all 7)
id Description Frequency HPO Source Accession
1 weight loss hallmark (90%) HP:0001824
2 nausea and vomiting hallmark (90%) HP:0002017
3 constipation hallmark (90%) HP:0002019
4 abdominal pain hallmark (90%) HP:0002027
5 abnormality of the peritoneum hallmark (90%) HP:0002585
6 abnormality of the abdominal wall hallmark (90%) HP:0004298
7 ovarian neoplasm hallmark (90%) HP:0100615

Drugs & Therapeutics for Primary Peritoneal Carcinoma

About this section

Drug clinical trials:

Search ClinicalTrials for Primary Peritoneal Carcinoma

Search NIH Clinical Center for Primary Peritoneal Carcinoma

Genetic Tests for Primary Peritoneal Carcinoma

About this section

Anatomical Context for Primary Peritoneal Carcinoma

About this section

MalaCards organs/tissues related to Primary Peritoneal Carcinoma:

32
Ovary, Brain, Eye, Lymph node, Breast, Testes, Endothelial

Animal Models for Primary Peritoneal Carcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Primary Peritoneal Carcinoma:

36 (show all 24)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053708.7EGFR, ERCC1, IL10, IFNG, TP53
2MP:00053678.5TP53, BRCA1, RET, IFNG, ERCC1, EGFR
3MP:00053828.3TP53, IFNG, IL10, ERBB2, EGFR
4MP:00053718.3TP53, BRCA2, BRCA1, PGR, RET, IL10
5MP:00053888.3TP53, BRCA1, RET, IFNG, IL10, ERBB2
6MP:00030128.3TP53, PGR, RET, IFNG, IL10, EGFR
7MP:00053818.1TP53, BRCA2, BRCA1, RET, IFNG, IL10
8MP:00053697.9TP53, BRCA1, PGR, RET, IFNG, IL10
9MP:00053867.9TP53, BRCA2, BRCA1, PGR, RET, IFNG
10MP:00053907.9TP53, BRCA2, BRCA1, PGR, IFNG, IL10
11MP:00107717.9TP53, BRCA2, BRCA1, PGR, IFNG, IL10
12MP:00028737.9TP53, BRCA2, BRCA1, PGR, RET, IFNG
13MP:00053857.8TP53, BRCA1, PGR, CXCL10, RET, IFNG
14MP:00036317.8TP53, BRCA2, BRCA1, CXCL10, RET, IFNG
15MP:00020067.7EGFR, TP53, BRCA2, BRCA1, PGR, RET
16MP:00053797.7TP53, BRCA2, BRCA1, PGR, RET, IFNG
17MP:00053807.7PGR, BRCA1, BRCA2, TP53, RET, IFNG
18MP:00053787.7TP53, BRCA2, BRCA1, RET, IFNG, IL10
19MP:00053897.7PGR, BRCA1, BRCA2, TP53, RET, IFNG
20MP:00053847.4PGR, BRCA1, BRCA2, TP53, CXCL10, RET
21MP:00053977.4PGR, BRCA1, BRCA2, TP53, CXCL10, RET
22MP:00053877.4TP53, BRCA2, BRCA1, PGR, CXCL10, RET
23MP:00053767.4TP53, BRCA2, BRCA1, PGR, CXCL10, RET
24MP:00107687.3TP53, BRCA2, BRCA1, PGR, CXCL10, RET

Publications for Primary Peritoneal Carcinoma

About this section

Articles related to Primary Peritoneal Carcinoma:

(show top 50)    (show all 109)
idTitleAuthorsYear
1
Cytoreductive surgery under aminolevulinic Acid-mediated photodynamic diagnosis plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from ovarian cancer and primary peritoneal carcinoma: results of a phase I trial. (25056850)
2014
2
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. (24709487)
2014
3
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. (25016924)
2014
4
Solitary primary peritoneal carcinoma arising from the omentum. (25017281)
2014
5
Treatment and prognostic factors in primary peritoneal carcinoma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). (24903764)
2014
6
Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma. (24798935)
2014
7
Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma. (24073344)
2013
8
Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182. (23791702)
2013
9
The effect of age on first-line chemotherapy for epithelial ovarian cancer and primary peritoneal carcinoma. (23146339)
2013
10
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. (22710075)
2012
11
A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. (22446624)
2012
12
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. (22037316)
2012
13
Prognosis of primary peritoneal carcinoma: effect of cytoreductive surgery combined with neoadjuvant chemotherapy after laparoscopic diagnosis and evaluation: a multi-center trial. (22439406)
2012
14
A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. (22943879)
2012
15
Pax-8 is a reliable marker in making the diagnosis in advanced stage epithelial ovarian carcinoma and primary peritoneal carcinoma for neoadjuvant chemotherapy on cell block and biopsy specimens. (22348438)
2012
16
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. (22772063)
2012
17
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma. (22047770)
2012
18
A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. (22155262)
2012
19
Primary peritoneal carcinoma in complete remission: a case report. (22199305)
2011
20
Peritoneal tuberculosis: a retrospective review of 20 cases and comparison with primary peritoneal carcinoma. (20973271)
2010
21
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. (20846715)
2010
22
The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional review. (21045830)
2010
23
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. (19162309)
2009
24
RET/PTC rearrangement occurring in primary peritoneal carcinoma. (19147513)
2009
25
Primary peritoneal carcinoma in a young woman with suspected endometriosis. (19327764)
2009
26
Primary peritoneal carcinoma: computed tomography and magnetic resonance findings. (18664839)
2008
27
Advanced primary peritoneal carcinoma: clinicopathological and prognostic factor analyses. (18543395)
2008
28
Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma. (17257661)
2007
29
Colorectal resection in patients with ovarian and primary peritoneal carcinoma. (16730631)
2006
30
Primary peritoneal carcinoma in a UK cancer center: comparison with advanced ovarian carcinoma over a 5-year period. (16515579)
2006
31
Primary peritoneal carcinoma: a rare neoplasm with pleomorphic trophoblastic morphology. (16907865)
2006
32
Negative laparoscopy is highly predictive of negative second-look laparotomy following chemotherapy for ovarian, tubal, and primary peritoneal carcinoma. (16769104)
2006
33
Asymptomatic primary peritoneal carcinoma presenting as adenocarcinoma on routine cervical cytology. (16553187)
2006
34
Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels. (16564077)
2006
35
Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study. (15589582)
2005
36
Is semen an etiologic factor in the development of primary peritoneal carcinoma and epithelial ovarian cancer? (15607552)
2005
37
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. (15542803)
2004
38
Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. (14615451)
2003
39
Axillary lymphadenopathy as the primary presentation of primary peritoneal carcinoma. (12592068)
2002
40
Prolonged symptom-free survival in a patient with persistent primary peritoneal carcinoma and a rising CA-125: a note of caution. (11371148)
2001
41
Extreme drug resistance assay and response to chemotherapy in patients with primary peritoneal carcinoma. (10738268)
2000
42
Solitary brain metastasis indicating recurrent primary peritoneal carcinoma. (10912420)
1999
43
Importance of lymph node metastases in primary peritoneal carcinoma. (9701204)
1998
44
Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma. (9692840)
1998
45
Extraovarian primary peritoneal carcinoma. (9644683)
1998
46
Prognostic factors in extraovarian primary peritoneal carcinoma. (9826465)
1998
47
Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin. (9367697)
1997
48
Primary peritoneal carcinoma: a treatable subset of patients with adenocarcinoma of unknown primary. (8602811)
1996
49
Surgically documented responses to paclitaxel and cisplatin in patients with primary peritoneal carcinoma. (8690292)
1996
50
Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. (8467455)
1993

Variations for Primary Peritoneal Carcinoma

About this section

Expression for genes affiliated with Primary Peritoneal Carcinoma

About this section
Expression patterns in normal tissues for genes affiliated with Primary Peritoneal Carcinoma

Search GEO for disease gene expression data for Primary Peritoneal Carcinoma.

Pathways for genes affiliated with Primary Peritoneal Carcinoma

About this section

Pathways related to Primary Peritoneal Carcinoma according to GeneCards/GeneDecks:

(show top 50)    (show all 53)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
10.0BRCA1, BRCA2
29.8BRCA1, TP53
39.8BRCA1, TP53
49.8IL10, IFNG
59.7ERCC1, BRCA1, BRCA2
6
Show member pathways
9.7BRCA2, BRCA1, ERCC1
79.7EGFR, IL8
89.6RET, IL10, IL8
99.5BRCA1, IFNG, IL8
10
Show member pathways
9.5BRCA1, BRCA2, TP53
119.5TP53, BRCA2, BRCA1
12
Show member pathways
Transcription NF kB signaling pathway60
Immune response Toll like receptor TLR ligands and common TLR signaling pathway leading to cell proinflammatory response60
9.5IL8, IFNG, CXCL10
13
Show member pathways
Development ERBB family signaling60
Development GDNF family signaling60
9.5RET, ERBB2, EGFR
149.5RET, ERBB2, EGFR
159.4IL8, IL10, IFNG
169.4IFNG, IL10, IL8
179.4IFNG, IL10, IL8
189.4IFNG, ERBB2, EGFR
199.3EGFR, ERBB2, TP53
20
Show member pathways
9.3TP53, ERBB2, EGFR
21
Show member pathways
Signal transduction PTEN pathway60
9.3EGFR, ERBB2, TP53
229.3TP53, ERBB2, EGFR
23
Show member pathways
ErbB receptor signaling network37
ErbB signaling pathway37
9.3EGFR, ERBB2, TP53
24
Show member pathways
9.3TP53, ERBB2, EGFR
259.3IL8, IFNG, TP53
269.3IL8, IFNG, TP53
27
Show member pathways
Immune response MIF in innate immunity response60
9.3IL8, IFNG, TP53
28
Show member pathways
9.3ERCC1, BRCA1, BRCA2, TP53
29
Show member pathways
9.3ERCC1, BRCA1, BRCA2, TP53
309.3EGFR, IL8, TP53
31
Show member pathways
9.2TP53, IFNG, EGFR
329.2TP53, IFNG, EGFR
339.1TP53, BRCA2, BRCA1, EGFR
34
Show member pathways
9.1TP53, CXCL10, IFNG, IL8
35
Show member pathways
9.0EGFR, ERBB2, BRCA2, TP53
36
Show member pathways
8.9TP53, IFNG, ERBB2, EGFR
378.9TP53, MIR497, MIR195
38
Show member pathways
8.9EGFR, ERBB2, IL8, IL10, CXCL10
39
Show member pathways
8.8TP53, BRCA2, BRCA1, ERBB2, EGFR
408.8TP53, BRCA2, BRCA1, ERBB2, EGFR
41
Show member pathways
Toll-like receptor signaling pathway37
Regulation of toll-like receptor signaling pathway37
8.7TP53, CXCL10, IFNG, IL10, IL8
428.7TP53, CXCL10, IFNG, IL8, EGFR
43
Show member pathways
Signaling Pathways in Glioblastoma37
8.5EGFR, ERBB2, IL8, BRCA1, BRCA2, TP53
448.5TP53, BRCA1, MIR195, ERBB2, EGFR
45
Show member pathways
8.5TP53, PGR, CXCL10, IL8, ERBB2, EGFR
468.4TP53, BRCA2, RET, IL8, ERBB2, EGFR
47
Show member pathways
8.4TP53, CXCL10, IL10, IL8, ERBB2, EGFR
48
Show member pathways
8.2TP53, BRCA1, CXCL10, IL10, IL8, ERBB2
49
Show member pathways
8.0TP53, BRCA1, IFNG, IL10, IL8, ERBB2
50
Show member pathways
8.0TP53, CXCL10, IFNG, IL10, IL8, ERBB2

Compounds for genes affiliated with Primary Peritoneal Carcinoma

About this section

Compounds related to Primary Peritoneal Carcinoma according to GeneCards/GeneDecks:

(show top 50)    (show all 175)
idCompoundScoreTop Affiliating Genes
1topotecan44 1110.7EGFR, MUC16, BRCA1
2vinorelbine44 50 1111.7EGFR, ERCC1, ERBB2, BRCA1
3fluticasone propionate44 50 61 1112.5IFNG, IL8, CXCL10, PGR
4polyinosinic-polycytidylic acid449.5IL10, IFNG, CXCL10, IL8
5capecitabine44 50 1111.5EGFR, ERBB2, PGR
6il 10449.4CXCL10, IFNG, IL10, IL8
7tarc449.4IL8, IFNG, IL10, CXCL10
8taxane449.4EGFR, TP53, PGR, ERBB2
9ccl344 2810.4CXCL10, IFNG, IL10, IL8
10neopterin449.3IL8, IL10, CXCL10, IFNG
11resveratrol44 61 24 1112.3PGR, ERBB2, BRCA1, BRCA2, TP53
12hydrocortisone44 2 61 1112.2IL10, IFNG, ERBB2, IL8, CXCL10
13methotrexate50 44 1111.2IL10, PGR, ERBB2, BRCA2, BRCA1, ERCC1
14suberoylanilide hydroxamic acid449.2EGFR, ERBB2, IFNG, TP53
15bortezomib44 50 1111.2EGFR, BRCA1, ERBB2, TP53
16herbimycin a44 6110.1RET, IFNG, IL8, ERBB2, EGFR
174-hydroxytamoxifen449.0ERBB2, BRCA1, PGR, IFNG, BRCA2, EGFR
18melphalan44 50 1111.0ERCC1, TP53, MUC16, IFNG
19etoposide44 50 61 1112.0BRCA2, ERCC1, ERBB2, BRCA1, TP53
20gemcitabine44 50 1110.9IL10, ERBB2, TP53, ERCC1, EGFR, BRCA1
21thymidylate448.9TP53, BRCA1, IL10, ERBB2, ERCC1, EGFR
22tamoxifen44 50 28 1111.9BRCA2, BRCA1, PGR, ERBB2, EGFR, TP53
23leucovorin44 50 1110.8CEACAM5, EGFR, ERCC1, ERBB2, PGR
24docetaxel44 50 61 1111.7TP53, EGFR, BRCA2, BRCA1, PGR, ERCC1
25gold448.7CXCL10, BRCA2, CEACAM5, BRCA1, MUC16
26ly294002448.7ERBB2, IL8, RET, IL10, TP53, EGFR
27irinotecan44 50 1110.6ERCC1, ERBB2, EGFR, CEACAM5, TP53
28cyclophosphamide44 50 1110.6TP53, BRCA1, PGR, MUC16, ERCC1, IL10
29agar448.6ERBB2, CEACAM5, RET, PGR, EGFR, BRCA1
30mitomycin c448.6TP53, BRCA2, ERCC1, BRCA1, CEACAM5, IL10
31testosterone44 61 24 1111.5BRCA1, PGR, MUC16, ERBB2, EGFR, BRCA2
32adriamycin448.5ERBB2, CEACAM5, TP53, BRCA2, PGR, BRCA1
33sb 20358044 619.5IL8, EGFR, IFNG, TP53, IL10
34oxaliplatin44 50 1110.5BRCA1, TP53, CEACAM5, ERBB2, ERCC1, EGFR
35carboplatin44 50 1110.4ERBB2, ERCC1, BRCA1, EGFR, IFNG, MUC16
36dexamethasone44 50 28 1111.4CXCL10, IFNG, IL10, IL8, PGR, MUC16
37retinoic acid44 249.3BRCA2, PGR, CXCL10, RET, IFNG, EGFR
38genistein44 28 61 2 24 1113.2CXCL10, IL8, EGFR, ERBB2, IFNG, RET
39paclitaxel44 50 1110.2ERBB2, BRCA1, ERCC1, EGFR, MUC16, PGR
40phosphatidylinositol448.1ERBB2, CEACAM5, RET, CXCL10, BRCA1, BRCA2
41thymidine44 248.9BRCA1, IL10, ERCC1, IFNG, TP53, CEACAM5
42butyrate447.9TP53, RET, IFNG, IL8, CEACAM5
435fluorouracil447.8PGR, BRCA1, CEACAM5, EGFR, ERCC1, TP53
44cycloheximide447.7CXCL10, PGR, BRCA1, BRCA2, IL10, ERBB2
45doxorubicin44 50 119.6EGFR, ERBB2, CEACAM5, MUC16, PGR, BRCA1
46cisplatin44 50 61 1110.6BRCA2, BRCA1, MUC16, CEACAM5, ERBB2, ERCC1
47progesterone44 28 61 24 1111.4EGFR, ERBB2, TP53, BRCA2, BRCA1, PGR
48estrogen447.1EGFR, CEACAM5, TP53, BRCA2, BRCA1, ERCC1
49paraffin447.1TP53, BRCA1, PGR, MUC16, RET, CEACAM5
50vegf446.1EGFR, TP53, BRCA1, ERBB2, IL8, IL10

GO Terms for genes affiliated with Primary Peritoneal Carcinoma

About this section

Cellular components related to Primary Peritoneal Carcinoma according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1receptor complexGO:0432359.6EGFR, ERBB2, RET
2transcription factor TFIID complexGO:0056699.5TP53, ERCC1
3endosome membraneGO:0100089.4EGFR, ERBB2, RET
4nucleoplasmGO:0056549.0ERCC1, PGR, BRCA1, BRCA2, TP53
5basolateral plasma membraneGO:0163238.9CEACAM5, ERBB2, EGFR
6extracellular spaceGO:0056158.4EGFR, MUC16, CXCL10, IFNG, IL10, IL8

Biological processes related to Primary Peritoneal Carcinoma according to GeneCards/GeneDecks:

(show all 23)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of MHC class II biosynthetic processGO:04534810.1IFNG, IL10
2response to molecule of bacterial originGO:00223710.0IL10, IL8
3embryonic organ developmentGO:04856810.0ERCC1, TP53
4negative regulation of growth of symbiont in hostGO:04413010.0IFNG, IL10
5DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:0069789.9BRCA1, BRCA2, TP53
6positive regulation of cell cycle arrestGO:0711589.9BRCA1, TP53
7cellular response to estradiol stimulusGO:0713929.9IL10, EGFR
8response to X-rayGO:0101659.9TP53, BRCA2, ERCC1
9response to gamma radiationGO:0103329.9TP53, BRCA2, CXCL10
10nucleotide-excision repairGO:0062899.8TP53, BRCA2, ERCC1
11peptidyl-tyrosine phosphorylationGO:0181089.8EGFR, ERBB2, RET
12cell agingGO:0075699.8BRCA2, TP53
13cellular response to lipopolysaccharideGO:0712229.7IL8, IL10, IFNG
14double-strand break repairGO:0063029.6ERCC1, BRCA1, BRCA2, TP53
15positive regulation of DNA repairGO:0457399.5EGFR, BRCA1
16protein import into nucleus, translocationGO:0000609.5IFNG, TP53
17cell surface receptor signaling pathwayGO:0071669.5EGFR, ERBB2, IFNG, CXCL10
18cell cycle arrestGO:0070509.4IL8, IFNG, TP53
19cell proliferationGO:0082839.3EGFR, ERCC1, ERBB2, TP53
20positive regulation of transcription, DNA-templatedGO:0458939.3TP53, BRCA2, BRCA1, RET, IL10
21signal transductionGO:0071659.0EGFR, ERBB2, IL8, RET, CXCL10, PGR
22positive regulation of transcription from RNA polymerase II promoterGO:0459448.8EGFR, IL10, IFNG, CXCL10, BRCA1, TP53
23negative regulation of apoptotic processGO:0430668.5TP53, CEACAM5, IL10, EGFR

Molecular functions related to Primary Peritoneal Carcinoma according to GeneCards/GeneDecks:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1epidermal growth factor-activated receptor activityGO:0050069.9EGFR, ERBB2
2transmembrane receptor protein tyrosine kinase activityGO:0047149.7EGFR, ERBB2, RET
3receptor signaling protein tyrosine kinase activityGO:0047169.5ERBB2, EGFR
4protein tyrosine kinase activityGO:0047139.4EGFR, ERBB2, RET
5protein phosphatase bindingGO:0199039.3TP53, ERBB2, EGFR
6enzyme bindingGO:0198999.2TP53, BRCA1, PGR, EGFR
7identical protein bindingGO:0428028.5EGFR, ERBB2, CEACAM5, TP53
8protein bindingGO:0055157.1PGR, BRCA1, BRCA2, TP53, MUC16, CXCL10

Products for genes affiliated with Primary Peritoneal Carcinoma

About this section
  • Antibodies
  • Proteins
  • Lysates

Sources for Primary Peritoneal Carcinoma

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
34MeSH
35MESH via Orphanet
36MGI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
58SNOMED-CT via Orphanet
62UMLS
63UMLS via Orphanet